BioSpace News Archive

Intelligent Bio Solutions Inc., a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for its fiscal fourth quarter and full-year ended June 30, 2023, and provided a business update.

LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023.

Radiopharm Theranostics is pleased to announce an expanded agreement with TerThera to supply the Company with Terbium-161.

Zhongchao Inc. announced it has achieved a milestone of serving over 10,000 breast cancer patients in China with comprehensive disease management services since 2021.

Antheia announced the successful completion of its first 116,000L scale manufacturing run with a commercially-relevant fermentation titer for its debut product.

Agilent Technologies Inc. announced the issuing of a companion diagnostic Class C IVDR certification for PD-L1 IHC 22C3 pharmDx, Code SK006.

Exelixis, Inc. (Nasdaq: EXEL) today announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the phase 3 CABINET pivotal trial early due to a dramatic improvement in efficacy that was observed at an interim analysis.

OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced its financial results for the fourth quarter and fiscal year ended June 30, 2023.

Ascendis Pharma A/S announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in three upcoming investor conferences.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company) today announced that it has developed a novel tablet formulation of IkT-148009, designed to improve drug exposure and overcome existing challenges related to patient use.